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Background: The risk of osteoporosis and fracture influences the selection of adjuvant endocrine therapy. We
analyzed bone mineral density (BMD) in Swiss patients of the Breast International Group (BIG) 1-98 trial [treatment
arms: A, tamoxifen (T) for 5 years; B, letrozole (L) for 5 years; C, 2 years of T followed by 3 years of L; D, 2 years of L
followed by 3 years of T].
Patients and methods: Dual-energy X-ray absorptiometry (DXA) results were retrospectively collected. Patients
without DXA served as control group. Repeated measures models using covariance structures allowing for different
times between DXA were used to estimate changes in BMD. Prospectively defined covariates were considered as
fixed effects in the multivariable models.
Results: Two hundred and sixty-one of 546 patients had one or more DXA with 577 lumbar and 550 hip measurements.
Weight, height, prior hormone replacement therapy, and hysterectomy were positively correlated with BMD; the
correlation was negative for letrozole arms (B/C/D versus A), known osteoporosis, time on trial, age, chemotherapy, and
smoking. Treatment did not influence the occurrence of osteoporosis (T score < 22.5 standard deviation).
Conclusions: All aromatase inhibitor regimens reduced BMD. The sequential schedules were as detrimental for
bone density as L monotherapy.
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introduction
Aromatase inhibitors (AIs) are currently part of the standard
endocrine therapy in postmenopausal women with early-stage
endocrine-sensitive breast cancer [1]. Large randomized trials
showed that AIs have a good tolerance and safety profile.
However, most of the studies reported a significantly higher
rate of bone fractures [2–7], osteoporosis, or osteopenia
measured by dual-energy X-ray absorptiometry [7–10] and
increase of bone resorption markers compared with tamoxifen
[8–10]. Therefore, bone health is a concern when initiating AIs
in the adjuvant setting.
In the general population, 30%–50% of postmenopausal
women are at risk of osteoporotic fractures [11].
Osteoporosis is a major public health problem as its
complications cause significant morbidity [12], alter quality
of life [13], and may lead to increased mortality [14].
Estrogen up-regulates the expression of osteoprotegerin,
suppresses apoptosis in osteoblasts, and down-regulates the
secretion of cytokines promoting osteoclast differentiation
[15, 16]. At menopause, estrogens produced by the aromatase
activity in the peripheral tissues play a protective role for
bone [17]. Since AIs decrease circulating estrogen levels
by >90% [18], they reinforce the unfavorable imbalance
between bone reabsorption and bone formation observed
after menopause [9, 10]. The risk of osteoporosis and
fractures therefore worries oncologists as well as patients and
influences the decision of whether to use an AI, tamoxifen, or
sequences of both. It is therefore important to have reliable
information to help in assessing the risk of bone fractures
when deciding to select between different types of endocrine
therapy.
All the large randomized studies compared up-front
treatment with 5 years of tamoxifen versus either 5 years of an
AI or a sequential schedule of 2–3 years of tamoxifen followed
by 2–3 years of an AI. The Breast International Group (BIG)
1-98 trial, with a four-arm design, is the only study assessing
simultaneously the up-front and the sequential use of an AI
in 8010 postmenopausal patients [6]: arm A, tamoxifen for
5 years; arm B, letrozole for 5 years; arm C, tamoxifen for
2 years followed by letrozole for 3 years; arm D, letrozole for
2 years followed by tamoxifen for 3 years. The original BIG
1-98 trial did not require bone mineral density (BMD)
measurement but did record predefined expected adverse
events including bone events every 6 months [2]. After
a median follow-up of 60.3 months, a significantly higher rate
of fractures was observed in the letrozole monotherapy arm
compared with the tamoxifen arm, 9.3% versus 6.5%,
respectively [2]. Although fracture is the most clinically
relevant end point, BMD is currently the best surrogate in the
prevention setting [19] and has been chosen by the World
Health Organization as the main diagnostic criterion for
osteoporosis.
Despite BMD measurements not being a study
requirement, many investigators have determined BMD in
their patients at different time points during and after the
completion of study treatments particularly after the first
published results of the Arimidex, Tamoxifen, Alone or in
Combination (ATAC) trial [20], which reported a higher rate
of bone fractures with anastrozole. The aim of our study was
to collect all available BMD measurements of all the BIG 1-98
patients treated in Switzerland irrespective of the bone health
status at study entry and to develop a statistical model to
describe the evolution of BMD in patients treated in the
different arms of BIG 1-98 trial. This was the unique
opportunity for a direct comparison between monotherapy
and sequential schedules of tamoxifen and an AI in
a randomized and double-blinded study.
patients and methods
patient selection
The patients included in the BIG 1-98 trial were all postmenopausal
women. The eligibility criteria of the patients accrued in BIG 1-98 trial are
described elsewhere [21]. Hormone replacement therapy (HRT) had to be
stopped at least 4 weeks before initiation of the trial treatment.
Concomitant bisphosphonates were allowed and their use was recorded
during the trial.
All the patients enrolled in the BIG 1-98 trial by Swiss centers were
considered for study entry. Exclusion criteria were as follows: withdrawal
of informed consent, known uncontrolled endocrine disease having an
impact on bone health (thyroid, parathyroid, Cushing’s, pituitary
diseases) or any other disease affecting bone health (other than breast
cancer and its therapy), adjuvant endocrine therapy for breast cancer
other than tamoxifen and letrozole, or metastatic bone disease before the
first BMD.
study design
Data were collected from the International Breast Cancer Study Group
(IBCSG) Data Center and the patients’ medical files. The IBCSG provided
the SAKK with the list of all Swiss patients enrolled in the BIG 1-98 study
and the following data: (i) at baseline: unblinded treatment arm, date of
inclusion, date of treatment start, age, skeletal-related events (fracture and
date), history of osteoporosis, weight, height, prior HRT, oophorectomy,
hysterectomy, tobacco history, bisphosphonate use, neoadjuvant or
adjuvant chemotherapy, time on treatment, bone disease, other diseases
affecting bone health, and uncontrolled endocrine diseases; (ii) during the
treatment period: visit dates, bisphosphonate use, patients with breast
cancer relapse and date of relapse, study treatment continuation, bone
fractures (date, cause, and site), uncontrolled endocrine disease, and
patients randomly allocated to the tamoxifen-only arm who switched to
letrozole; (iii) follow-up data: visit dates, patients with breast cancer relapse
and date of relapse, uncontrolled endocrine disease, and bone fractures
(date, cause, and site).
A research associate collected BMD measurements from each center for
up to 3 years before inclusion in the BIG 1-98 trial. For patients with
none or only one BMD available at the center, the patients’ general
practitioner and/or gynecologist were contacted in order to know if any
additional BMD measurement had been done. The following data were
collected for each patient: radiology center, date of assessment, name and
characteristics of the used machine, level of measure in the lumbar spine,
BMD (g/cm2), T score, and Z score [% and standard deviation (SD)] for
lumbar spine and total hip.
The study was carried out in accordance with the Declaration of
Helsinki, the Guidelines of Good Clinical Practice issued by the
International Conference on Harmonization, and the Swiss regulatory
authority’s requirements. The study was approved by the local ethics
committees and the Swiss ‘Experts’ commission of professional secrecy
for medical research’.
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statistical considerations
The data were first split into two groups: one group containing patients
with at least one recorded BMD measurement and the second group
containing patients with no BMD measurements. The second group
was used as a bias assessment group in order to detect any between-
group imbalance in baseline characteristics. To reduce bias, such
imbalanced characteristics have been included in the final statistical
model.
All baseline variables included in the analysis were summarized
descriptively: frequency (percentage) by category for categorical variables
and median (quartile range) for continuous variables. This was done
individually for both the study group and the bias assessment group and the
two groups compared using a Chi-squared test for the categorical variables
and the Mann–Whitney–Wilcoxon test for continuous variables.
Differences between treatment arms were not considered during the
descriptive analysis as patients had been randomly assigned to the treatment
arms, stratified according to the participating center and neo/adjuvant
chemotherapy use.
The statistical model used to describe BMD changes was a repeated
measures model that allowed for multiple BMD measurements from
individual patients. To use as much of the available information as
possible, the first BMD measurement was included in the response
variable along with the BMD measurements collected after
randomization. The first-order autoregressive covariance structure was
used in the model to allow for the differences in time between different
BMD measurements. All covariates considered to be of importance in the
prediction of BMD were first considered in a univariate model as fixed
effects before being considered simultaneously in a multivariate model.
When modeling BMD change, the time to the BMD measurement was
also considered and recorded in months from the time of BIG 1-98 trial
registration. Machine type and center were modeled as random variables
in the mixed repeated measures model to allow for natural variation
between center and machine type used in the BMD measurement
recordings. Other variables remaining in the model were considered to be
the risk factors and their influence on the BMD shown. A smoothed line
was plotted through the actual data points per treatment arm based on
the actual BMD measurement against time.
Due to the significant number of patients in arm A that crossed over to
letrozole [6], BMD measurements were modeled using the intention-to-
treat (ITT) principle as well as the per-protocol (PP) principle. This means
that the patients in treatment arm A were analyzed using the trial therapy as
intended and not allowing for the unplanned crossover under the ITT
principle, while the PP principle means their observations were ignored
after the time of crossover.
role of the funding source
Novartis had no role in the study design, data analyses, or results
interpretation.
results
A total of 546 patients (arm A, 133; B, 137; C, 141; and D,
135) from 11 centers were included in this study (Figure 1).
Overall, 261 of them (48%) had at least one BMD
measurement (Table 1). One patient was excluded due to
unrealistic BMD values. Patients’ baseline characteristics are
described in Table 2. No major differences were observed
between patients with BMD measurements and those
without. Less than 1% of the patients were using
bisphosphonates at baseline. Six patients in arm A, three in
arm B, and one in arm D received bisphosphonates during
study treatment. The median baseline T scores were 21.15
SD and 20.60 SD in the lumbar spine and hip, respectively.
The patients with osteoporosis represented 6.2% of the
studied population. The numbers of patients presenting
lumbar osteopenia were 27, 23, 22, and 29 in arms A, B, C,
and D, respectively. Those with hip osteopenia were 21, 26,
21, and 24, respectively.
A total of 577 lumbar BMD measurements were collected:
arm A, 155; arm B, 150; arm C, 132; and arm D, 140. The
proportion of patients with more than one BMD was 73%
(n = 179). The number of the total hip measurements recorded
was 550: arm A, 150; arm B, 142; arm C, 132; and arm D, 126.
The median number of measurements per patient was two for
both locations. Sixty percent (n = 349) of the BMD were
measured during the endocrine treatment period and 40%
(n = 228) during the following years (Table 3).
In the univariate and multivariate analyses, treatment in
any of the letrozole-containing arms and history of
osteoporosis were significant predictors of lumbar spine
BMD loss. Higher weight and height, previous hysterectomy,
and HRT use were associated with less BMD loss. The
multivariate analyses also revealed time since randomization
as a significant negative factor (Table 4). For the total hip
BMD, the univariate analyses showed treatment in arm B,
age, history of osteoporosis, smoking (current versus never),
and bisphosphonate use as predictors of BMD loss, whereas
weight and height were predictors of BMD preservation. In
the multivariate analyses, the association of all these
parameters was still significant except for bisphosphonate use
and height. In addition, not only treatment arm B but all the
letrozole-containing arms were significant predictors of
increased bone loss compared with the tamoxifen-only
treated patients (Table 5). When analyzing the treatment
arms as predictors of osteoporosis, defined as a T score £
22.5 SD, none of them showed a statistically significant
impact. The data based on the ITT principle were concordant
with those based on the PP principle (not presented).
discussion
The results of our analysis show that in all three letrozole-
containing arms, the loss of BMD is significantly higher than
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) diagram.
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in the tamoxifen-only arm. Contrary to expectations, the
sequential administration of tamoxifen followed by letrozole
has no long-term protective effect on BMD despite the
shorter exposure to AI and the previous administration of
tamoxifen (Figure 2). Patients treated with tamoxifen
increased their BMD but observed a deep fall when switching
Table 1. Study patients’ distribution
Type of measurement Number of patients per treatment arm Total number of patients
A B C D
Lumbar BMD 66 63 55 62 246
Lumbar T score 66 63 59 63 251
Total hip BMD 65 59 56 56 236
Total hip T score 61 55 51 53 220
BMD, bone mineral density.
Table 2. Baseline characteristics of the eligible population
Factors Patients with
No BMD measured (n = 285) One or more BMD measured (n = 261) P value
Continuous factors Median (quartile range)
Weight (kg) 67 (44 to 117) 65 (43 to 114) 0.006
Height (cm) 163 (146 to 180) 162 (145 to 182) 0.180
Age at randomization (years) 63 (47 to 86) 61 (41 to 81) 0.017
Lumbar BMDa, g/cm2 0.962 (0687 to 1.474)
Lumbar T score SD BMDa 21.15 (23.30 to 3.60)
Total hip BMDa, g/cm2 0891 (0.613 to 1.127)
Total hip T score SD BMDa 2060 (23.00 to 1.20)
Categorical factors n (%)
Race, white 285 (99.65) 260 (100.00) 1.000
Osteoporosis 7 (2.45) 16 (6.15) 0.031
Smoking
Previously 35 (12.28) 39 (15.06) 0.254
Ongoing 57 (20.00) 39 (15.06)
Never 193 (67.72) 181 (69.88)
Bone fracture (last 10 years) 17 (5.94) 18 (6.92) 0.641
Hysterectomy 98 (34.27) 71 (27.31) 0.079
HRT within the last 5 years 125 (43.70) 129 (49.61) 0.519
Using bisphosphonate 1 (0.35) 2 (0.77) 0.795
Neo/adjuvant chemotherapy 77 (26.92) 98 (37.69) 0.007
aUsing nearest recorded measurement to randomization date (within 6 1 to 3 years).
BMD, bone mineral density; HRT, hormone replacement therapy; SD, standard deviation.
Table 3. BMD measurements since randomization
Years since randomization Lumbar BMD (n = 577) Total hip BMD (n = 550)
Treatment arms
A B C D A B C D
0–1 9 15 5 10 9 14 5 10
1–2 4 9 12 6 4 9 12 5
2–3 19 11 19 10 19 10 19 7
3–4 19 24 15 25 19 21 15 22
4–5 40 37 32 29 40 37 33 26
5–6 38 35 28 31 36 33 29 30
6–7 22 15 16 21 20 14 15 19
>7 6 4 5 8 5 4 4 7
BMD, bone mineral density.
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to letrozole after 2 years, particularly in the lumbar spine.
Conversely, starting with letrozole induced a loss, but the
switch to tamoxifen after 2 years improved BMD
considerably. This hypothesis is also supported by the bone
fracture rate reported in the BIG 1-98 main trial [6]. The
incidence of fractures among women assigned to tamoxifen
or letrozole followed by tamoxifen was lower than in women
treated with tamoxifen followed by letrozole or letrozole
alone (7.3%, 7.5%, 9.4%, and 9.8%, respectively).
Tamoxifen is known to increase or to stabilize bone density
and to decrease fracture rate in postmenopausal patients [22].
The reason why there is no persisting benefit after 2 years of
tamoxifen during the following AI treatment in terms of BMD
is not known so far. However, a rebound phenomenon is
suspected. The interruption of tamoxifen combined with the
rapid fall in estrogen levels induced by the AI may promote an
accelerated loss of BMD following the switch [7, 23, 24].
McCaig et al. [25] reported that stopping tamoxifen and
starting AIs results in a significantly greater increase in bone
turnover compared with commencing AIs in tamoxifen-naive
patients. The measurement of bone turnover biomarkers also
showed that the effect of AIs occurs relatively rapidly after
initiation of the treatment [9, 24, 26–29].
Bone fracture rates in the AI arms reported in the large
randomized trials were higher with the up-front use of AIs
than with the sequential administration of tamoxifen
followed by AI: ATAC trial (68 months), 11% versus 7.7%;
BIG 1-98 trial monotherapy arms (51 months), 8.6% versus
5.8%; Austrian Breast and Colorectal Cancer Study Group
(ABCSG)/Arimidex-Nolvadex (ARNO) trial (28 months),
Table 4. Univariate and multivariate analysis of lumbar spine BMD predictors (ITT)
Factor Estimate (standard error)
Category Univariate P value Multivariate P value
Age (years) 20002 (0001) 00892 2
Weight (kg) 0002 (0001) <00001 0002 (0001) <00001
Height (cm) 0005 (0001) <0001 0004 (0001) 00005
Hysterectomy Yes versus no 0052 (0015) 00005 0057 (0014) <00001
Osteoporosis Yes versus no 20113 (0026) <00001 20138 (0025) <00001
Smoking status Current versus never 0030 (0019) 01204 0028 (0019) 01429
Did versus never 0072 (0017) <00001 0071 (0016) <00001
HRT Yes versus no 0029 (0013) 00275 0031 (0014) 00239
Bisphosphonate use Continuing versus never 20138 (0088) 01179 –
Treatment arm B versus A 20051 (0018) 00053 20042 (0017) 00132
C versus A 20078 (0019) <0001 20073 (0018) <00001
D versus A 20058 (0019) 00019 20047 (0017) 00071
Previous neo/adjuvant
chemotherapy
Yes versus no 0014 (0014) 02863 –
Time since randomization 20004 (0004) 01832 20010 (0004) 00051
BMD, bone mineral density; HRT, hormone replacement therapy; ITT, intention-to-treat.
Table 5. Univariate and multivariate analysis of total hip BMD predictors (ITT)
Factor Estimate (standard error)
Category Univariate P value Multivariate P value
Age (years) 20004 (0001) <00001 20004 (0001) <00001
Weight (kg) 0004 (0001) <00001 0004 (0004) <00001
Height (cm) 0003 (0001) 00003 –
Hysterectomy Yes versus no 0021 (0012) 00815 –
Osteoporosis Yes versus no 20100 (0021) <00001 20084 (0019) <00001
Smoking status Current versus never 20032 (0016) 00481 20047 (0015) 00013
Did versus never 0018 (0014) 01765 0013 (0012) 02768
HRT Yes versus no 0010 (0011) 03518 0.022 (0.009) 00174
Bisphosphonate use Continuing versus never 20156 (0070) 00250 –
Treatment arm B versus A 20035 (0014) 00159 20039 (0012) 00015
C versus A 20022 (0015) 01281 20041 (0013) 00015
D versus A 20017 (0015) 02601 20032 (0013) 00119
Previous neo/adjuvant
chemotherapy
Yes versus no 20012 (0011) 02691 –
Time since randomization 20001 (0003) 08980 –
BMD, bone mineral density; HRT, hormone replacement therapy; ITT, intention-to-treat.
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2% versus 1%; Inter-Group Exemestane (IES) trial, 7%
versus 4.9%. However, the odds ratio in the control arm
appears to be similar between the up-front AI (ATAC and
BIG 1-98 trials) and the switch schedules (IES and ABCSG/
ARNO trials). The fracture rates in the ATAC, BIG 1-98
monotherapy arms and IES trials were 21.6, 22.0, and 20.1
per 1000 patients per year, respectively [30]. This supports
the absence of a significant persistent bone protective effect
of 2–3 years of tamoxifen when followed by AI. These
observations are, however, not in accordance with the
findings of the Tamoxifen Exemestane Adjuvant
Multinational (TEAM) trial investigating 5 years of
exemestane alone versus 2–3 years of tamoxifen followed by
exemestane [31]. They reported a lower rate of fracture and
osteoporosis in the sequential arm (3% versus 5% and 6%
versus 10%, respectively) [32]. The results of the prospective
bone substudy of BIG 1-98 trial will soon bring additional
information.
In addition to the endocrine therapy, our model also
highlights other factors that may have a significant impact on
BMD changes during treatment such as weight, height, age,
time since randomization, history of osteoporosis, previous
hysterectomy, HRT, and smoking. All these parameters are
known to influence bone density and fracture risk in the
general population. The significance of hysterectomy as
a protective factor is unclear, but it could be a surrogate
marker for prior estrogen exposure and its associated
endometrial pathologies [33]. Patients with higher estrogen
exposure might have a more resistant bone structure and also
an increased risk of uterine adverse events leading to
hysterectomy.
In our model, the allocation of the treatment arm did not
significantly influence the occurrence of osteoporosis,
defined as a T score <22.5 SD. This is in line with the results
of the ATAC bone substudy presented by Eastell et al. [8].
Patients with initially normal BMD had a low risk of
developing osteoporosis secondary to the endocrine therapy.
Some limitations have to be considered in our study. First,
BMD is not a perfect surrogate marker for fracture risk.
Indeed, most fractures occur even if the threshold of
osteoporosis is not reached [34]. BMD reflects mainly bone
cortical mass and is poorly representative of the
microarchitecture [35]. Secondly, this is not a prospectively
randomized trial but a statistical modeling study based on
unplanned BMD measurements; therefore, the results have to
be considered with caution. The retrospective collection of
the measurements did not allow central quality control of the
BMDs even if machine types and centers were modeled as
random variables. Despite data on many factors known to
influence bone health being available and considered in our
model (age, weight, height, smoking, personal history of
fracture, osteoporosis, previous HRT, bisphosphonate use,
and previous neo/adjuvant chemotherapy), others (calcium
and vitamin D use, medications known to influence bone
turnover, nutrition, physical activity, parathyroid hormone
level, time since menopause, and family history of hip
fracture) were not available. Nevertheless, the comparison
between the different treatment arms, the initial
randomization and the multivariate analyses might have
attenuated the risk of imbalance. No major difference was
observed between the study population and the
noninvestigated group of Swiss patients treated in BIG 1-98
trial (bias assessment group). The characteristics of our study
population were also similar to those of the BIG 1-98 main
study in terms of age, body mass index, history of
bisphosphonate use, history of bone fractures, smoking, and
HRT use before randomization [2]. In addition, only 12%
of the data cover the first 2 years of treatment and 22%
3 years. Our model has therefore more influence for the last
years of treatment. The prior inclusion of all patients in this
analysis is a strength of the study minimizing the selection
bias seen with most bone substudies of AI trials requesting
predefined bone entry criteria. Nevertheless, despite the
described measures of caution, the influence of other
unknown confounders is not excluded.
As the prognosis of early breast cancer patients improves, the
long-term safety of adjuvant treatment is increasingly
important. Based on our results and other concordant data
described above, the decision on whether to administer
up-front AI versus a sequential schedule of tamoxifen followed
Figure 2. Bone mineral density evolution over time: (A) lumbar; (B) total hip.
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by AI should not be based on bone health considerations but
rather on other factors, i.e. clinical tolerance, cost,
comorbidities, risk of relapse, and patient’s preference.
Several studies showed that bisphosphonates [36] or
denosumab [37] could successfully stabilize bone density
during endocrine therapy with AIs at least in
nonosteoporotic patients. The risk of osteoporosis and bone
fracture can be managed by following the published experts’
recommendations [38, 39]. Our observation refers to
postmenopausal women. The impact of endocrine treatment
on bone health in premenopausal women is unknown; for
premenopausal patients, investigation of BMD changes and
bone remodeling is ongoing in the Tamoxifen and
Exemestane (TEXT) trial.
In conclusion, our study shows that all AI regimens, up-
front or sequential, affect BMD to different degrees.
Contrary to expectation, the switch strategy starting with
tamoxifen before AI administration does not seem to confer
a protective effect on bone health. The converse regimen, AI
followed by tamoxifen, may offer a better benefit in terms of
efficacy and bone safety [6]. The results of this unplanned
and retrospective substudy of the BIG 1-98 trial need future
confirmation.
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